Nvidia, Broadcom, and AMD Investors Need to Have Oct. 15 Circled on Their Calendars

TSMC is expected to report Q3 results on Oct. 15, with July and August revenue already up 45% and 53% year over year, respectively, supporting Wall Street's estimated 47% quarterly revenue growth. The key catalysts are potential 2027 AI-demand guidance and possible foundry price increases, which could benefit TSMC and affect captive customers Nvidia, AMD, and Broadcom. At roughly 27x forward earnings versus its typical year-end multiple near 30x, the article argues shares could rise sharply only if TSMC materially beats expectations or signals stronger pricing power.

Analysis

The relevant Oct. 15 setup is not the reported quarter but whether TSM can monetize its scarcity through leading-edge wafer pricing and sustain node mix into 2027. A realized price/mix uplift would expand TSM gross margin faster than revenue and validate an upward earnings-reset cycle; it would also expose the AI chip designers’ differing pass-through power. NVDA is best positioned to absorb higher wafer costs given system-level pricing, while AMD’s lower gross-margin buffer and more price-sensitive accelerator roadmap make it the relative loser; AVGO should be comparatively insulated by custom-chip contracts and diversified semiconductor content.

The market’s likely error is treating a foundry price increase as uniformly negative for AI semis. It is initially a modest COGS headwind, but it simultaneously confirms capacity remains constrained and that hyperscaler demand has not normalized—supportive for NVDA and AVGO revenue visibility over the next 1-3 quarters. The more material negative readthrough would be commentary that advanced packaging availability, not wafer starts, is the binding constraint: this shifts economics toward packaging and test vendors such as ASE Technology (ASX) and Amkor (AMKR), while delaying customer revenue recognition.

Near term, an in-line print with no incremental 2027 capacity, pricing, or margin language leaves TSM vulnerable to post-event multiple compression because the visible growth trajectory is already broadly embedded. Over 6-18 months, the structural risk is geographic diversification: incremental U.S./Japan capacity lowers customer concentration risk but can dilute consolidated margins if utilization or government support disappoints. Falsify the constructive thesis if management signals a reduction in leading-edge utilization, gross-margin guide-down despite strong sales, or customer inventory digestion; those outcomes would challenge the scarcity premium rather than merely defer it.

Key Decisions for Investors

• Maintain/establish a 1-3 month pair: long TSM / short AMD, sized beta-neutral. TSM captures any pricing and mix upside directly, while AMD has less room to pass incremental foundry costs through; target 8-12% relative upside, with stop-loss if TSM guides gross margin lower or AMD demonstrates offsetting accelerator-share gains.
• For event exposure, buy TSM Nov-2026 call spreads rather than outright shares only if implied volatility is below the prior four-quarter post-earnings move. Structure a near-ATM/10%-OTM spread to monetize a pricing-plus-2027-guide catalyst while capping downside from an in-line outcome.
• Stay long NVDA through the readout but avoid adding solely on a TSM beat. Add only if management confirms both demand visibility and capacity availability; a wafer-price increase without incremental supply can constrain shipment upside even as it validates demand.
• Put ASX and AMKR on a 1-3 month buy watchlist. Initiate only if management identifies advanced packaging bottlenecks or raises related capex, which would redirect investor attention from chip designers to the capacity owners; absent that disclosure, there is no clean incremental catalyst.